v3.26.1
Segment Reporting - Schedule of Segment Net Loss, Including Disaggregated Components of Operating Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Collaboration revenue $ 773   $ 937   $ 1,807 $ 1,503
Research and development:            
Personnel expenses 6,876   4,509   14,077 8,214
Manufacturing costs 4,065   10,000   9,038 12,129
Professional fees and other 1,857   1,079   3,487 2,571
Total research and development expenses 36,089   37,865   72,654 63,662
General and administrative:            
Personnel expenses 4,328   3,773   9,265 8,005
Professional fees 1,538   2,397   3,572 3,893
Other 1,186   1,249   2,299 2,303
Total general and administrative expenses 7,052   7,419   15,136 14,201
Total operating expenses 43,141   45,284   87,790 77,863
Loss from operations (42,368)   (44,347)   (85,983) (76,360)
Other income (expense):            
Interest income 2,659   4,431   5,713 9,174
Other income (expense), net 7   (50)   (23) (50)
Total other income, net 2,666   4,381   5,690 9,124
Net loss (39,702) $ (40,591) (39,966) $ (27,270) (80,293) (67,236)
COPD Indication            
Research and development:            
Verekitug program 8,348   6,803   19,310 12,490
Asthma Indication            
Research and development:            
Verekitug program 12,943   13,236   23,653 23,257
CRSwNP Indication            
Research and development:            
Verekitug program $ 2,000   $ 2,238   $ 3,089 $ 5,001